STTK has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
STTK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Shattuck Labs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.82 Mil. Shattuck Labs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $3.19 Mil. Shattuck Labs's annualized EBITDA for the quarter that ended in Mar. 2024 was $-76.28 Mil. Shattuck Labs's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.05.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's
The historical rank and industry rank for Shattuck Labs's Debt-to-EBITDA or its related term are showing as below:
During the past 6 years, the highest Debt-to-EBITDA Ratio of Shattuck Labs was -0.05. The lowest was -0.05. And the median was -0.05.
The historical data trend for Shattuck Labs's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shattuck Labs Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Debt-to-EBITDA | Get a 7-Day Free Trial | - | - | - | -0.05 | -0.05 |
Shattuck Labs Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Debt-to-EBITDA | Get a 7-Day Free Trial | -0.05 | -0.05 | -0.04 | -0.06 | -0.05 |
For the Biotechnology subindustry, Shattuck Labs's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Shattuck Labs's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Shattuck Labs's Debt-to-EBITDA falls into.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Shattuck Labs's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (0.796 | + | 3.406) | / | -87.915 | |
= | -0.05 |
Shattuck Labs's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (0.821 | + | 3.193) | / | -76.28 | |
= | -0.05 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.
Shattuck Labs (NAS:STTK) Debt-to-EBITDA Explanation
In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.
Be Aware
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's
Thank you for viewing the detailed overview of Shattuck Labs's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Andrew R Neill | officer: See Remarks | 1018 W 11TH STREET, SUITE 100, AUSTIN TX 78703 |
Stephen Stout | officer: See Remarks | C/O SHATTUCK LABS, INC., 500 W. 5TH STREET, SUITE 1200, AUSTIN TX 78701 |
George Golumbeski | director | C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901 |
Abhinav A. Shukla | officer: Chief Technical Officer | 500 W. 5TH STREET, SUITE 1200, AUSTIN TX 78701 |
Carrie Brownstein | director | 500 W. 5TH ST., SUITE 1200, AUSTIN TX 78701 |
Erin Ator Thomson | officer: General Counsel | 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703 |
Josiah Hornblower | director, 10 percent owner, officer: Chairman | 3317 BOWMAN AVE, AUSTIN TX 78703 |
Taylor Schreiber | director, officer: Chief Executive Officer | 100 EUROPA DRIVE, CHAPEL HILL NC 27517 |
Redmile Group, Llc | director, 10 percent owner | ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129 |
Helen M Boudreau | director | 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139 |
Neil W Gibson | director | C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121 |
Tyler Brous | director | 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703 |
Casi Deyoung | officer: Chief Business Officer | C/O MIRNA THERAPEUTICS, INC., 2150 WOODWARD ST., SUITE 100, AUSTIN TX 78744 |
Arundathy N. Pandite | officer: Chief Medical Officer | 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703 |
Victor Stone | director | 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703 |
From GuruFocus
By sperokesalga sperokesalga • 05-09-2023
By GuruFocusNews GuruFocusNews • 07-01-2022
By GlobeNewswire GlobeNewswire • 04-05-2022
By GuruFocusNews GuruFocusNews • 06-01-2022
By GuruFocusNews GuruFocusNews • 05-22-2022
By Business Wire Business Wire • 04-05-2022
By sperokesalga sperokesalga • 03-01-2023
By PurpleRose PurpleRose • 07-11-2022
By GuruFocusNews GuruFocusNews • 06-21-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.